1. Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy
   Jonathan Grimm et al, 2021, Journal of Clinical Medicine CrossRef
2. Evaluation of Cardiovascular Risk Factors after Hepatitis C Virus Eradication with Direct-Acting Antivirals in a Cohort of Treatment-Naïve Patients without History of Cardiovascular Disease
   Diego Casas-Deza et al, 2022, Journal of Clinical Medicine CrossRef
3. The Role of PCSK9 in Infectious Diseases
   Laura Magnasco et al, 2022, Current Medicinal Chemistry CrossRef
4. Serum lipid profile in HCV patients treated with direct-acting antivirals: a systematic review and meta-analysis
   Rosanna Villani et al, 2021, Scientific Reports CrossRef
5. Serum Ceramide Species Are Associated with Liver Cirrhosis and Viral Genotype in Patients with Hepatitis C Infection
   Marcus Höring et al, 2022, International Journal of Molecular Sciences CrossRef
6. Treatment of Hepatitis C Virus Infection with Direct-acting Antiviral Agents Elevates the Serum Small-dense Low-density Lipoprotein Cholesterol Level
   Naoyuki Hino et al, 2021, Internal Medicine CrossRef
7. Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond
   Thomas Grewal et al, 2022, International Journal of Molecular Sciences CrossRef